Bank of America
CRNX icon

Bank of America’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bank of America’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26M Sell
716,125
-85,189
-11% -$3.8M ﹤0.01% 2169
2025
Q4 		$37.3M Buy
801,314
+200,272
+33% +$8.92M ﹤0.01% 1765
2025
Q3 		$25M Buy
601,042
+27,760
+5% +$888K ﹤0.01% 2392
2025
Q2 		$16.5M Buy
573,282
+268,356
+88% +$8.29M ﹤0.01% 2752
2025
Q1 		$10.2M Buy
304,926
+69,645
+30% +$2.6M ﹤0.01% 3114
2024
Q4 		$12M Sell
235,281
-42,792
-15% -$2.39M ﹤0.01% 2764
2024
Q3 		$14.2M Sell
278,073
-27,096
-9% -$1.4M ﹤0.01% 2729
2024
Q2 		$13.7M Sell
305,169
-51,973
-15% -$2.4M ﹤0.01% 2625
2024
Q1 		$16.7M Buy
357,142
+12,729
+4% +$498K ﹤0.01% 2460
2023
Q4 		$12.3M Buy
344,413
+189,513
+122% +$5.81M ﹤0.01% 2655
2023
Q3 		$4.61M Buy
154,900
+34,526
+29% +$711K ﹤0.01% 3483
2023
Q2 		$2.17M Sell
120,374
-56,099
-32% -$1.12M ﹤0.01% 4159
2023
Q1 		$2.83M Buy
176,473
+52,406
+42% +$970K ﹤0.01% 4053
2022
Q4 		$2.27M Buy
124,067
+64,610
+109% +$1.14M ﹤0.01% 4136
2022
Q3 		$1.17M Buy
59,457
+5,171
+10% +$105K ﹤0.01% 4758
2022
Q2 		$1.01M Sell
54,286
-43,648
-45% -$871K ﹤0.01% 4889
2022
Q1 		$2.15M Buy
97,934
+29,837
+44% +$604K ﹤0.01% 4515
2021
Q4 		$1.94M Buy
68,097
+56,475
+486% +$1.39M ﹤0.01% 4598
2021
Q3 		$245K Sell
11,622
-1,487
-11% -$31.1K ﹤0.01% 6167
2021
Q2 		$247K Buy
13,109
+789
+6% +$13.9K ﹤0.01% 5950
2021
Q1 		$188K Sell
12,320
-7,000
-36% -$108K ﹤0.01% 6086
2020
Q4 		$272K Sell
19,320
-1,000
-5% -$13.9K ﹤0.01% 5395
2020
Q3 		$318K Sell
20,320
-514
-2% -$7.86K ﹤0.01% 5019
2020
Q2 		$365K Buy
20,834
+11,398
+121% +$194K ﹤0.01% 4848
2020
Q1 		$139K Sell
9,436
-3,562
-27% -$73K ﹤0.01% 5322
2019
Q4 		$326K Buy
12,998
+1,690
+15% +$32.2K ﹤0.01% 5316
2019
Q3 		$170K Sell
11,308
-1,305
-10% -$25.4K ﹤0.01% 5761
2019
Q2 		$316K Sell
12,613
-17,331
-58% -$429K ﹤0.01% 5374
2019
Q1 		$682K Buy
29,944
+24,012
+405% +$590K ﹤0.01% 4805
2018
Q4 		$179K Buy
5,932
+4,689
+377% +$132K ﹤0.01% 5589
2018
Q3 		$36K Buy
+1,243
New +$36.9K ﹤0.01% 6334

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bank of America's CRNX Position: Q1 2026 in Review

Bank of America reduced its Crinetics Pharmaceuticals (CRNX) stake by 11% in Q1 2026, selling an estimated $3.8M and leaving 716,125 shares worth $26M. The position accounts for ﹤0.01% of the portfolio, ranked #2169.

Bank of America first reported a position in CRNX in Q3 2018 and has held it in 31 quarters since. The position peaked at $37.3M in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Bank of America held 716,125 shares of Crinetics Pharmaceuticals worth $26M as of Q1 2026.
  • Bank of America sold 85,189 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $3.8M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2169 holding.
  • Bank of America first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Bank of America's Crinetics Pharmaceuticals position peaked at $37.3M in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.